PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced the availability of a new, minimally-invasive nasal swab collection option as a part of its comprehensive SARS-CoV-2 (COVID-19) testing program. BusinessWire
Wednesday, June 3, 2020
Minimally invasive nasal swab collection option benefits both patients and healthcare providers
PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced the availability of a new, minimally-invasive nasal swab collection option as a part of its comprehensive SARS-CoV-2 (COVID-19) testing program. BusinessWire
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment